Backgrounds The effectiveness of oral antiviral therapy including nirmatrelvir plus ritonavir
and molnupiravir in managing COVID-19 among individuals with pre-existing lung cancer …

Purpose: Immunocompromised individuals, such as those diagnosed with cancer, are at a
significantly higher risk for severe illness and mortality when infected with SARS-CoV-2 …

Background/Aim: The Covid-19 epidemic has severely strained health care systems across
the globe. The impacts are multiple especially for patients cared for cancer. The Covid-19 …

Background The coronavirus disease 2019 (COVID-19) pandemic poses a great challenge
to the treatment of lung cancer patients. Materials and methods The PubMed, Embase, and …

Background Cancer patients appear to be at a higher risk of complications from coronavirus
disease 2019 (COVID-19). Specific data related to lung cancer (LC) patient management …

Background COVID-19 is spreading rapidly worldwide, and the population is generally
susceptible to SARS-CoV-2, especially those with cancer. Hence, our study aims to design a …

Cancer is considered to be an independent risk factor for severe illness and higher mortality
in patients with coronavirus disease 2019 (COVID-19). These adverse outcomes have been …

Simple Summary The results of previous studies may suggest that Nirmatrelvir/Ritonavir,
when evaluated against placebo controls, could potentially be more effective than …

Background Currently there are no reported series determining the Covid-19 infected lung
cancer patient´ s characteristics and outcome that allow us to clarify strategies to protect our …

Background Lung cancer patients with coronavirus disease 2019 (COVID-19) infection
experience high mortality rates. The study aims to determine the risk factors for mortality in …